Literature DB >> 16339811

B-type natriuretic peptide can detect silent myocardial ischaemia in asymptomatic type 2 diabetes.

B S Rana1, J I Davies, M M Band, S D Pringle, A Morris, A D Struthers.   

Abstract

OBJECTIVE: To find out whether B-type natriuretic peptide (BNP) detects silent myocardial ischaemia in patients with type 2 diabetes, since many of these patients have silent ischaemia leading to unexpected cardiac deaths.
DESIGN: Prospective cross-sectional study with consecutive recruitment of patients.
SETTING: Outpatient, single centre. PATIENTS: 219 patients with type 2 diabetes. Patients were excluded if they had a history or evidence of cardiac failure. OUTCOME MEASURES: BNP, echocardiography and exercise tolerance test (ETT). BNP was compared with the ETT result in all patients and specifically in those who had no apparent ischaemic heart disease (IHD).
RESULTS: 121 patients had no history of IHD or cardiac failure and of these patients 85 had a clearly abnormal or normal ETT result. BNP was higher in patients with an abnormal than with a normal ETT (mean 58.2 (SD 46.3) v 24.4 (SD 15.7) pg/ml, p < 0.001). In univariate analysis BNP was an independent predictor of an abnormal ETT (p < 0.001). In multivariate analysis BNP remained an independent predictor of the ETT result. BNP concentration over 20 pg/ml predicted an abnormal ETT result with a sensitivity of 87% and specificity of 37%, and BNP over 40 pg/ml had a sensitivity of 63% and a specificity of 81%.
CONCLUSION: BNP is of value in predicting silent ischaemia on exercise testing in asymptomatic patients with type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16339811      PMCID: PMC1860694          DOI: 10.1136/hrt.2005.071423

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  31 in total

1.  EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events.

Authors: 
Journal:  Eur Heart J       Date:  1997-10       Impact factor: 29.983

2.  Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria.

Authors:  P Gaede; P Hildebrandt; G Hess; H-H Parving; O Pedersen
Journal:  Diabetologia       Date:  2004-12-24       Impact factor: 10.122

3.  Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy.

Authors:  L Tarnow; P Hildebrandt; B V Hansen; K Borch-Johnsen; H-H Parving
Journal:  Diabetologia       Date:  2004-12-23       Impact factor: 10.122

4.  Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction.

Authors:  B Stanek; B Frey; M Hülsmann; R Berger; B Sturm; J Strametz-Juranek; J Bergler-Klein; P Moser; A Bojic; E Hartter; R Pacher
Journal:  J Am Coll Cardiol       Date:  2001-08       Impact factor: 24.094

5.  The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes.

Authors:  J A de Lemos; D A Morrow; J H Bentley; T Omland; M S Sabatine; C H McCabe; C Hall; C P Cannon; E Braunwald
Journal:  N Engl J Med       Date:  2001-10-04       Impact factor: 91.245

Review 6.  The natriuretic peptides in heart failure: diagnostic and therapeutic potentials.

Authors:  H H Chen; J C Burnett
Journal:  Proc Assoc Am Physicians       Date:  1999 Sep-Oct

7.  Significance of silent ischemia and microalbuminuria in predicting coronary events in asymptomatic patients with type 2 diabetes.

Authors:  Martin K Rutter; Shahid T Wahid; Janet M McComb; Sally M Marshall
Journal:  J Am Coll Cardiol       Date:  2002-07-03       Impact factor: 24.094

8.  Out-of-hospital cardiac arrest in the 1990's: a population-based study in the Maastricht area on incidence, characteristics and survival.

Authors:  J J de Vreede-Swagemakers; A P Gorgels; W I Dubois-Arbouw; J W van Ree; M J Daemen; L G Houben; H J Wellens
Journal:  J Am Coll Cardiol       Date:  1997-11-15       Impact factor: 24.094

9.  Screening for silent myocardial ischaemia in type 2 diabetic patients with additional atherogenic risk factors: applicability and accuracy of the exercise stress test.

Authors:  S Bacci; M Villella; A Villella; T Langialonga; M Grilli; A Rauseo; S Mastroianno; S De Cosmo; R Fanelli; V Trischitta
Journal:  Eur J Endocrinol       Date:  2002-11       Impact factor: 6.664

10.  Use of a prognostic treadmill score in identifying diagnostic coronary disease subgroups.

Authors:  L J Shaw; E D Peterson; L K Shaw; K L Kesler; E R DeLong; F E Harrell; L H Muhlbaier; D B Mark
Journal:  Circulation       Date:  1998-10-20       Impact factor: 29.690

View more
  14 in total

1.  The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial.

Authors:  M D Witham; F J Dove; M Dryburgh; J A Sugden; A D Morris; A D Struthers
Journal:  Diabetologia       Date:  2010-07-02       Impact factor: 10.122

2.  Sex Hormones and Change in N-Terminal Pro-B-Type Natriuretic Peptide Levels: The Multi-Ethnic Study of Atherosclerosis.

Authors:  Wendy Ying; Di Zhao; Pamela Ouyang; Vinita Subramanya; Dhananjay Vaidya; Chiadi E Ndumele; Kavita Sharma; Sanjiv J Shah; Susan R Heckbert; Joao A Lima; Christopher R deFilippi; Matthew J Budoff; Wendy S Post; Erin D Michos
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

3.  Acute and chronic effects of exercise on inflammatory markers and B-type natriuretic peptide in patients with coronary artery disease.

Authors:  Juliano Lara Fernandes; Carlos Vicente Serrano; Flavia Toledo; Maria Fernanda Hunziker; Augusto Zamperini; Fabio H Teo; Romulo T Oliveira; Maria Heloisa Blotta; Maria Urbana Rondon; Carlos Eduardo Negrão
Journal:  Clin Res Cardiol       Date:  2010-09-12       Impact factor: 5.460

4.  B-type natriuretic peptide (BNP) levels in female systemic lupus erythematosus patients: what is the clinical significance?

Authors:  Omer Karadag; Meral Calguneri; Bunyamin Yavuz; Enver Atalar; Ali Akdogan; Umut Kalyoncu; Sedat Kiraz; Serdar Aksoyek; Ferhan Ozmen; A Ihsan Ertenli
Journal:  Clin Rheumatol       Date:  2007-02-21       Impact factor: 2.980

5.  Relationship between natriuretic peptides and echocardiography parameters in patients with poorly regulated type 2 diabetes.

Authors:  Magnus Dencker; Martin Stagmo; Mozhgan Dorkhan
Journal:  Vasc Health Risk Manag       Date:  2010-06-01

6.  B-type natriuretic peptide release in the coronary effluent after acute transient ischaemia in humans.

Authors:  Domingo A Pascual-Figal; María J Antolinos; Antoni Bayes-Genis; Teresa Casas; Francisco Nicolas; Mariano Valdés
Journal:  Heart       Date:  2007-03-29       Impact factor: 5.994

7.  Early diagnosis of left ventricular diastolic dysfunction in diabetic patients: a possible role for natriuretic peptides.

Authors:  Silvio Romano; Michele Di Mauro; Simona Fratini; Leonello Guarracini; Fabrizio Guarracini; Gianfranco Poccia; Maria Penco
Journal:  Cardiovasc Diabetol       Date:  2010-12-16       Impact factor: 9.951

8.  Clinical significance of elevated B-type natriuretic peptide in patients with acute lung injury with or without right ventricular dilatation: an observational cohort study.

Authors:  Magda Cepkova; Vineet Kapur; Xiushui Ren; Thomas Quinn; Hanjing Zhuo; Elyse Foster; Michael A Matthay; Kathleen D Liu
Journal:  Ann Intensive Care       Date:  2011-06-13       Impact factor: 6.925

9.  A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction.

Authors:  Hari K Parthasarathy; Burkert Pieske; Marianne Weisskopf; Chris D Andrews; Patrick Brunel; Allan D Struthers; Thomas M MacDonald
Journal:  Eur J Heart Fail       Date:  2009-10       Impact factor: 15.534

10.  N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS.

Authors:  Paul Welsh; Orla Doolin; Peter Willeit; Chris Packard; Peter Macfarlane; Stuart Cobbe; Vilmundur Gudnason; Emanuele Di Angelantonio; Ian Ford; Naveed Sattar
Journal:  Eur Heart J       Date:  2012-08-31       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.